Eton Pharmaceuticals price target raised to $52 from $37 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Eton Pharmaceuticals (ETON) to $52 from $37 and keeps a Buy rating on the shares. Eton “unveiled its second set of corporate goals which are largely to become financially mature, a natural progression after building a strong operational specialty pharma company,” the analyst tells investors in a research note. The firm believes the company has a path to $500M in sales via new launches and acquisitions. H.C. Wainwright believes Eton “could potentially become the financially mature company it expects to be by the end of this decade.”